DiaSys Corporation Announces the Introduction of Parasep SF Solvent Free Parasite Concentrator
WATERBURY, Conn., Nov. 20 /PRNewswire-FirstCall/ — DiaSys Corporation (BULLETIN BOARD: DYXC) today announced the product introduction of Parasep SF, a solvent free fecal parasite concentrator that eliminates the need for ethyl acetate or ether derived products for the clean and efficient concentration of helminth ova and larvae and protozoal cysts and oocysts. The new dual filter technology removes the smaller fecal debris and solubilizes the fat content so that it does not interfere with the resulting sediment without the use of ether or ethyl acetate. The Parasep SF provides a safe, clean sample with excellent recovery of all parasite stages and removes the problems of operator risk and safe disposal. Parasep SF has been designed to fully integrate into the DiaSys Corporation FE-5 workstation that has now been modified by enlarging the viewable sample in its Optical Slide Assembly. This fully integrated system prevents the unauthorized use of other concentrators.
DiaSys Corporation launched the new product at the MEDICA trade show in Dusseldorf Germany, November 15-18, 2006.
“We are excited about the potential for Parasep SF. It will provide health and safety benefits for all product users. In the Andean countries where ether and ether-derived products are banned, Parasep SF will enable those countries to perform better testing for parasites. We look forward to expanding the Parasep SF product applications into areas that were previously unavailable to this technology” stated Gregory Witchel, Chief Executive Officer, DiaSys Corporation.
DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and through distributors in South America. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.
This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.
CONTACT: Gregory Witchel, Chief Executive Officer, DiaSys Corporation,+1-203-755-5083
Web site: http://www.diasys.com/